Wedbush restated their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a report issued on Monday, RTT News reports. Wedbush currently has a $15.00 price objective on the stock. Separately, HC Wainwright restated a buy rating and set a $16.00 target price on shares of Inozyme Pharma in a research note […]
Inozyme Pharma s (INZY) Outperform Rating Reaffirmed at Wedbush theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Wedbush Reiterates Outperform Rating for Inozyme Pharma (NASDAQ:INZY) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now owns 20,665 […]
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now […]